Core Viewpoint - The establishment of the Fangchenggang International Medical Open Experimental Zone has effectively addressed local pharmaceutical industry bottlenecks and facilitated the development of the medical industry, extending service chains to overseas markets, particularly in ASEAN countries [1] Group 1: Service System and Structure - The "One Station, Two Centers" service system was created to enhance the efficiency of the pharmaceutical industry in Fangchenggang, addressing issues such as weak industry foundation and lack of leading enterprises [1][2] - The system includes the Fangchenggang Service Workstation of the Guangxi Zhuang Autonomous Region Drug Administration and the Food and Drug Review and Inspection Center, providing comprehensive services from consultation to inspection [2] Group 2: Efficiency and Growth - The innovative service model has significantly improved local registration and approval efficiency, with the number of medical device registrations increasing from 3 in 2019 to 174, and the number of Class II medical device manufacturers rising from 3 to 40 [3] - The establishment of a local medical device review team has alleviated the shortage of professional talent by implementing a dual-channel personnel exchange mechanism with the regional level [2][3] Group 3: International Cooperation and Market Expansion - The Fangchenggang International Medical Open Experimental Zone has actively pursued international cooperation, organizing promotional activities in countries like Vietnam and Uzbekistan, and establishing a product export service station in Vietnam [3] - The zone has attracted nearly 200 domestic pharmaceutical companies and several foreign buyers through the China-ASEAN regional pharmaceutical trading platform, facilitating cross-border online transactions [4] Group 4: Future Development Plans - The city plans to further deepen reforms and optimize the "One Station, Two Centers" service mechanism, enhancing collaboration between policy, finance, and international expansion to establish the medical experimental zone as a hub for pharmaceutical innovation in the ASEAN region [4]